SMS Lifesciences India Limited has informed the Exchange regarding 'Investor Presentation for the quarter and year ended March 31, 2025.'.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Lifesciences reported FY25 consolidated revenue of ₹344.7 crore, up 12.7% YoY, with PAT jumping nearly 3x to ₹18.7 crore (up 196% YoY) and EBITDA up 43% to ₹49.9 crore. However, Q4FY25 was weak with consolidated PAT falling 46% YoY to ₹3.5 crore and EBITDA down 29% YoY, primarily due to a ₹4.34 crore provision for doubtful debts. The Board declared a ₹1.50 per share dividend for FY25 and approved a name change to Haleos Labs Limited, pending shareholder approval. The company highlighted ₹145 crore of capex since demerger, plans to expand its product portfolio to 50+ products by FY2028, successful USFDA inspections in January and May 2025, and a new US contract manufacturing project for Mahi Drugs set to start in FY26.
Strong full-year results with PAT nearly tripling YoY are positive, but Q4 weakness and the doubtful debt provision raise concerns about near-term quality of earnings. The name change and capex-led growth plans signal a strategic rebranding and expansion push that could support long-term growth if execution holds up.